Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

NEXT STORY
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
PREV STORY
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

NEWS RELEASE  REGULATED INFORMATION                                                                                                                    Data published in Journal of Urology reports over ...

author_avatar
NASDAQ Market News

RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel

author_avatar
NASDAQ Market News

Medical Imaging Market to Reach $43.33 Billion by 2027; Increasing Number of Product Launches by Major Companies will have a Massive Impact on Market Growth, says Fortune Business Insights™

author_avatar
NASDAQ Market News